Evans syndrome is a rare complication that develops in adults after liver transplantation. The possible etiologies include ABO mismatch, viral infection, post-transplantation lymphoproliferative disease, graft-versus-host disease, and the use of certain immunosuppressive drugs (e.g., calcineurin inhibitors). Here, we present a case of Evans syndrome that developed after an ABOmatched liver transplant. Glucocorticosteroid, intravenous immunoglobulin, and alternative immunosuppressant therapies all failed. Weekly rituximab (375 mg/m 2 ) was then administered for 4 weeks. The cytopenia improved transiently after the second dose of rituximab, but soon worsened again. However, the cytopenia normalized after a splenectomy. (Korean J Med 2015;88:464-468) 
INTRODUCTION
Evans syndrome (ES) comprises the triad of autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), and a positive direct antiglobulin test in the absence of any known underlying etiology. ES is a chronic disease that presents with frequent exacerbations and remissions [1] . ES following solid organ transplantation is a rare complication, with only a few reported cases [2] [3] [4] [5] [6] [7] . First-line ES therapy consists of corticosteroids and intravenous immunoglobulin (IVIG). Immunosuppressants, rituximab, splenectomy, and chemotherapy can also be administered when ES is refractory to first-line therapy [1] .
Here, we report a case of ES that developed in an ABOmatched liver transplant patient who was treated successfully with a splenectomy after failing to respond to steroids, IVIG, changes in the immunosuppressant therapy, or rituximab. 
CASE REPORT
A 51-year-old man visited our emergency room with a 3-day history of nausea, vomiting, general weakness, and dyspnea, but no abdominal pain. Six months prior, he had received a liver transplant from an ABO-matched donor because of hepatitis B and hepatocellular carcinoma, and he was receiving immunosuppressive therapy with mycophenolate mofetil 250 mg bid and ta- 3A and 3B). The patient's reticulocyte count and LDH levels were 24.12% and 676 IU/L, respectively ( Fig. 3C and 3D ). Beginning ES is a very rare complication of solid organ transplantation with only seven reported cases ( inhibitor such as sirolimus [9] . This mechanism might also lead to the development of ES following solid organ transplantation.
In our case, the donor was ABO-matched and there was no evidence of PTLD or GVHD. The EBV PCR titer was positive, but cytopenia persisted after the EBV PCR titer turned negative.
Tacrolimus was used for immunosuppression, but the change to sirolimus was ineffective.
In all seven reported cases of ES that developed after solid organ transplantation, corticosteroids and IVIG were administered as the first-line therapy. However, this disease was refractory to first-line therapy in all except one case that developed 8 months after liver transplantation. Rituximab was given as the second-line therapy in six cases, and remission was achieved in four cases. Fludarabine, splenectomy, and cyclosporine were used in the rituximab-refractory patients and a response was observed after a splenectomy and cyclosporine intervention [2] [3] [4] [5] [6] [7] .
This indicates that ES following solid organ transplantation is usually refractory to corticosteroids and IVIG and other treatment modalities should be considered, such as rituximab, splenectomy, or different immunosuppressants.
In summary, ES after solid organ transplantation is a rare hematological complication. Clinicians should remember that ES is one of the causes of anemia and thrombocytopenia in solid organ transplant patients. ES following solid organ transplantation is usually refractory to steroid therapy and IVIG. Therefore, additional treatment modalities need to be explored.
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